For informational purposes only.
Scleteri 14 mg
Scleteri 14 mg tablet tablet is prescribed to adults for the treatment of recurrent form of multiple sclerosis (MS) (the symptoms of the disease appear from time to time).
Scleteri 14 mg tablet Uses :-
Scleteri 14 mg tablet is used for the treatment of relapsing-remitting form of multiple sclerosis in adults.
Multiple sclerosis is a disease of the brain and spinal cord. In which nerves do not function properly, their own immune system attacks the protective sheath (called myelin) of the nerves. And it causes nerve damage. This causes symptoms such as numbness, loss of vision, fatigue, pain and loss of muscle coordination.
Scleteri 14 mg tablet works by limiting the function of specific immune cells that cause nerve damage in multiple sclerosis. In this way it prevents recurrence as well as slows down the progression of the disease.
Scleteri 14 mg tablet helps to suppress the body's immune system, preventing the return of symptoms. Teriflunomide slows down the progression of the disease and also reduces the inflammation of the damaged nerves, preventing further damage. Stabilizes your immune system.
Scleteri 14 mg tablet Composition :-
Teriflunomide .......................... 14 mg
Teriflunomide belongs to a class of drugs called immunomodulatory drugs.
Scleteri 14 mg tablet Dosage Forms & Strengths :-
Scleteri 14 mg tablet Dosage :-
Scleteri 14 mg tablet Sideeffects :-
Phosphatemia and many other side effects can occur.
How Scleteri 14 mg tablet ( Teriflunomide ) works:-
Teriflunomide -
Teriflunomide works by limiting the function of specific immune cells that cause nerve damage in multiple sclerosis. In this way it prevents recurrence as well as slows down the progression of the disease.
Teriflunomide helps to suppress the body's immune system, preventing the return of symptoms. Teriflunomide slows down the progression of the disease and also reduces the inflammation of the damaged nerves, preventing further damage. Stabilizes your immune system.
Precautions :-
Scleteri 14 mg tablet should not be used during pregnancy. Because it can harm the unborn baby.
Breastfeeding women should not use Scleteri 14 mg tablet. As it can pass into breast milk consult your doctor.
Regular urine and blood tests to monitor blood cells, liver, and kidney function may be required during treatment with Scleteri 14 mg tablet.
Before taking Scleteri 14 mg tablet tell your doctor if you are allergic to teriflunomide.
If you,
Liver problems,
Blood disorders/bone marrow,
Immune system disorders (such as those caused by cancer, HIV infection),
Recent infection (eg tuberculosis),
High blood pressure,
Lung disease etc.
Scleteri 14 mg tablet can make infections more likely or can worsen infections.
Scleteri 14 mg tablet should not be used during pregnancy. Because it can harm the unborn baby.
Breastfeeding women should not use Scleteri 14 mg tablet. As it can pass into breast milk consult your doctor.
Regular urine and blood tests to monitor blood cells, liver, and kidney function may be required during treatment with Scleteri 14 mg tablet.
Before taking Scleteri 14 mg tablet tell your doctor if you are allergic to teriflunomide.
If you,
Liver problems,
Blood disorders/bone marrow,
Immune system disorders (such as those caused by cancer, HIV infection),
Recent infection (eg tuberculosis),
High blood pressure,
Lung disease etc.
Scleteri 14 mg tablet can make infections more likely or can worsen infections.
Scleteri 14 mg tablet Price :-
MRP ₹ : 1140.00 ( 10 tabs )
MRP ₹ : 1140.00 ( 10 tabs )
Packing Information :-
Scleteri 14 mg tablet is available in pack of 10 tablets.
Scleteri 14 mg tablet Marketed By :-
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Scleteri 14 mg tablet Self life :-
Please see the expiry date/manufacture date printed on the Scleteri 14 mg tablet pack.
Please see the expiry date/manufacture date printed on the Scleteri 14 mg tablet pack.
Classification :-
Habit Forming - No
Drug - Teriflunomide
Therapeutic Class - Immunomodulatory, Multiple sclerosis,
Information on this page was last updated on 14 September 2021